X4 Pharmaceuticals Inc (XFOR) concluded trading on Thursday at a closing price of $0.81, with 7.73 million shares of worth about $6.26 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 20.24% during that period and on December 26, 2024 the price saw a gain of about 38.91%. Currently the company’s common shares owned by public are about 168.51M shares, out of which, 117.85M shares are available for trading.
Stock saw a price change of 25.67% in past 5 days and over the past one month there was a price change of 140.08%. Year-to-date (YTD), XFOR shares are showing a performance of -3.91% which decreased to -4.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.26 but also hit the highest price of $1.60 during that period. The average intraday trading volume for X4 Pharmaceuticals Inc shares is 3.18 million. The stock is currently trading 44.74% above its 20-day simple moving average (SMA20), while that difference is up 58.52% for SMA50 and it goes to 1.45% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
X4 Pharmaceuticals Inc (NASDAQ: XFOR) currently have 168.51M outstanding shares and institutions hold larger chunk of about 35.58% of that.
The stock has a current market capitalization of $137.41M and its 3Y-monthly beta is at 0.31. It has posted earnings per share of -$0.09 in the same period. It has Quick Ratio of 4.80 while making debt-to-equity ratio of 1.31. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XFOR, volatility over the week remained 20.75% while standing at 20.53% over the month.
Stock’s fiscal year EPS is expected to rise by 77.49% while it is estimated to decrease by -309.09% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on December 12, 2023 offering a Neutral rating for the stock and assigned a target price range of between $3 and $1 to it. Coverage by B. Riley Securities stated X4 Pharmaceuticals Inc (XFOR) stock as a Buy in their note to investors on August 30, 2023, suggesting a price target of $3 for the stock. On December 22, 2022, Cantor Fitzgerald Initiated their recommendations, while on December 12, 2022, Piper Sandler Initiated their ratings for the stock with a price target of $3. Stock get an Outperform rating from Oppenheimer on December 23, 2019.
